Gilberto de Castro

Gilberto de Castro

Auto-generated profile, based on publicly available information

Gilberto de Castro

Department of Oncology, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in The Lancet
Verified
Journal Article
Closed access
RHRoy S Herbst
Roy S Herbst
PBPaul Baas
Paul Baas
DKDong-Wan Kim
Dong-Wan Kim
EFEnriqueta Felip
Enriqueta Felip
JGJose Luis Perez Gracia
Jose Luis Perez Gracia
EGEdward B Garon
Edward B Garon

1 March 2017 in The Lancet
Verified
Journal Article
Closed access
JSJean-Charles Soria
Jean-Charles Soria
DTDaniel S W Tan
Daniel S W Tan
RCRita Chiari
Rita Chiari
YWYI-LONG WU
YI-LONG WU
LPLuis Paz-Ares
Luis Paz-Ares
GCGilberto de Castro
Gilberto de Castro

1 March 2017 in The Lancet
Verified
Journal Article
Closed access
DCDavid Cameron
David Cameron
MPMartine J Piccart-Gebhart
Martine J Piccart-Gebhart
RGRichard D Gelber
Richard D Gelber
MPMarion Procter
Marion Procter
AGAron Goldhirsch
Aron Goldhirsch
CJChristian Jackisch
Christian Jackisch

24 April 2007 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
EAEvandro de Azambuja
Evandro de Azambuja
FCF Cardoso
F Cardoso
GCG de Castro
G de Castro
MCM Colozza
M Colozza
MMM S Mano
M S Mano
MPM Paesmans
M Paesmans
The Ki-67 antigen is used to evaluate the proliferative activity of breast cancer (BC); however, Ki-67's role as a prognostic marker in BC is still undefined. In order to better define the prognostic value of Ki-67/MIB-1, we performed a meta-analysis of studies that evaluated the impact of Ki-67/MIB-1 on disease-free survival (DFS) and/or on overall survival (OS) in early BC. Sixty-eight studies were identified and 46 studies including 12 155 patients were evaluable for our meta-analysis; 38 studies were evaluable for the aggregation of results for DFS, and 35 studies for OS. Patients were considered to present positive tumours for the expression of Ki-67/MIB-1 according to the cut-off points defined by the authors. Ki-67/MIB-1 positivity is associated with higher probability of relapse in all patients (HR=1.93 (95% confidence interval (CI): 1.74–2.14); P<0.001), in node-negative patients (HR=2.31 (95% CI: 1.83–2.92); P<0.001) and in node-positive patients (HR=1.59 (95% CI: 1.35–1.87); P<0.001). Furthermore, Ki-67/MIB-1 positivity is associated with worse survival in all patients (HR=1.95 (95% CI: 1.70–2.24; P<0.001)), node-negative patients (HR=2.54 (95% CI: 1.65–3.91); P<0.001) and node-positive patients (HR=2.33 (95% CI: 1.83–2.95); P<0.001). Our meta-analysis suggests that Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC.

1 February 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
KHKevin Harrington
Kevin Harrington
BBBarbara Ann Burtness
Barbara Ann Burtness
RGRichard Greil
Richard Greil
DSDenis Soulieres
Denis Soulieres
MTMakoto Tahara
Makoto Tahara
DRDanny Rischin
Danny Rischin
PURPOSE: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and progression-free survival on next-line therapy (PFS2) is presented. METHODS: Patients were randomly assigned (1:1:1) to pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy. Efficacy was evaluated in programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20, CPS ≥ 1, and total populations, with no multiplicity or alpha adjustment. RESULTS: The median study follow-up was 45.0 months (interquartile range, 41.0-49.2; n = 882). At data cutoff (February 18, 2020), overall survival improved with pembrolizumab in the PD-L1 CPS ≥ 20 (hazard ratio [HR], 0.61; 95% CI, 0.46 to 0.81) and CPS ≥ 1 populations (HR, 0.74; 95% CI, 0.61 to 0.89) and was noninferior in the total population (HR, 0.81; 95% CI, 0.68 to 0.97). Overall survival improved with pembrolizumab-chemotherapy in the PD-L1 CPS ≥ 20 (HR, 0.62; 95% CI, 0.46 to 0.84), CPS ≥ 1 (HR, 0.64; 95% CI, 0.53 to 0.78), and total (HR, 0.71; 95% CI, 0.59 to 0.85) populations. The objective response rate on second-course pembrolizumab was 27.3% (3 of 11). PFS2 improved with pembrolizumab in the PD-L1 CPS ≥ 20 (HR, 0.64; 95% CI, 0.48 to 0.84) and CPS ≥ 1 (HR, 0.79; 95% CI, 0.66 to 0.95) populations and with pembrolizumab-chemotherapy in the PD-L1 CPS ≥ 20 (HR, 0.64; 95% CI, 0.48 to 0.86), CPS ≥ 1 (HR, 0.66; 95% CI, 0.55 to 0.81), and total (HR, 0.73; 95% CI, 0.61 to 0.88) populations. PFS2 was similar after pembrolizumab and longer after pembrolizumab-chemotherapy on next-line taxanes and shorter after pembrolizumab and similar after pembrolizumab-chemotherapy on next-line nontaxanes. CONCLUSION: With a 4-year follow-up, first-line pembrolizumab and pembrolizumab-chemotherapy continued to demonstrate survival benefit versus cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Patients responded well to subsequent treatment after pembrolizumab-based therapy.

1 July 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
KCK. Cocks
K. Cocks
MKM.T. King
M.T. King
GVG. Velikova
G. Velikova
GCG. de Castro
G. de Castro
MSM. Martyn St-James
M. Martyn St-James
JBJ.M. Brown
J.M. Brown